Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy

Summary

This study is a prospective, single arm, single center open clinical study aimed at evaluating the efficacy and safety of recombinant human endostatin and envafolimab combined with synchronal radiochemotherapy in patients with locally advanced squamous non-small cell lung cancer who cannot undergo surgery in stage III.

Timeline

Start

2024-02-18

Primary completion

2024-06-18

Completion

2025-12-18

Drugs

Indications